[The effect of dipyridamole on coagulation status in stenocardia].
The laboratory examination of Dipyridamole concerning its antiaggregation effect is presented in the paper. Thirty patients with coronary insufficiency have been taking Dipyridamole for one year. The average dosage was four pills à 75 mg of Dipyridamole a day. The aggregation and adhesion of the platelets with the examined patients was checked before and during the treatment. The inhibition platelet aggregation with Dipyridamole has been confirmed in vitro.
D000328:Adult; D000787:Angina Pectoris / Q000097:blood* / Q000188:drug therapy; D001777:Blood Coagulation / Q000187:drug effects*; D004176:Dipyridamole / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects
D004176:Dipyridamole
Efekat dipiridamola na koagulacijski status bolesnika sa stenokardijama.